Conference Coverage (ICAAC)

ACTG 175: First-Line AIDS Therapy Should Be Combination

Published in AIDS Weekly, October 2nd, 1995

The newly-released results of a major AIDS clinical trial support changing the first-line therapy for people with HIV infection.

Instead of monotherapy with zidovudine (AZT), the study shows that patients benefit more from combination therapy with AZT and either didanosine (ddI) or zalcitabine (ddC).

The trial, ACTG 175, showed that all treatments studied - ddI plus AZT, ddC plus AZT, and ddI alone - were superior to AZT monotherapy in delaying progression to AIDS, death, or precipitous decline of CD4⁺ T cells in patients with intermediate HIV disease (initial CD4 counts of 200 to 500 cells/(mu)L). The newer treatments provided a greater...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry